Immunocore Holdings annual r&d spending
2021
2022
2023
2024
2025
Immunocore Holdings R&D Spending Growth & History (IMCR)
Immunocore Holdings's r&d spending was $274.9M for fiscal 2025.
View full Immunocore Holdings company overviewImmunocore Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $274.9M | $52.7M | +23.73% |
| 2024 | 2024-12-31 | $222.2M | $58.6M | +35.83% |
| 2023 | 2023-12-31 | $163.5M | $61.6M | +60.46% |
| 2022 | 2022-12-31 | $101.9M | $1.7M | +1.67% |
| 2021 | 2021-12-31 | $100.2M | — | — |
Immunocore Holdings quarterly r&d spending
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $73.9M | $4.9M | +7.15% |
| Q1 2026 | 2026-03-31 | $61.1M | $4.6M | +8.23% |
| Q4 2025 | 2025-12-31 | $78.8M | $18.0M | +29.53% |
| Q3 2025 | 2025-09-30 | $70.6M | $17.8M | +33.74% |
| Q2 2025 | 2025-06-30 | $69.0M | $17.9M | +35.12% |
| Q1 2025 | 2025-03-31 | $56.5M | −$991,000 | −1.72% |
| Q4 2024 | 2024-12-31 | $60.9M | $15.3M | +33.54% |
| Q3 2024 | 2024-09-30 | $52.8M | $9.5M | +22.01% |
| Q2 2024 | 2024-06-30 | $51.1M | $12.9M | +33.84% |
| Q1 2024 | 2024-03-31 | $57.5M | $20.9M | +57.11% |
| Q4 2023 | 2023-12-31 | $45.6M | — | — |
| Q3 2023 | 2023-09-30 | $43.2M | — | — |
| Q2 2023 | 2023-06-30 | $38.2M | — | — |
| Q1 2023 | 2023-03-31 | $36.6M | — | — |
Immunocore Holdings r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, Immunocore Holdings's r&d spending increased from $100.2M to $274.9M, a change of $174.6M. The latest reported quarter, Q2 2026, shows $73.9M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunocore Holdings source filings ↗